Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial Stats
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT07459192
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors
Overview
Based on this, the present study designed and constructed a novel multifunctional molecular DOTA-BLP and its radiolabeled derivative ⁶⁸Ga-DOTA-BLP, aiming to achieve dynamic monitoring of PD-L1 using PET imaging.
Sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase
N/A
Contacts
xiao chen, PH.D
xiaochen229@tmmu.edu.cn
15922970174
ClinicalTrials.gov
NCT07459192Drug / Compound
68Ga-DOTA-BLP
Isotope(s):
GALLIUM-68
Radioisotope: Ga-68
Theranostic Role: PET Imaging
T1/2 (Half-Life): 68 minutes
Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
Range: N/A
Decay Daughters: Zn68 (Stable)
Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
Target(s):
- 17β-estradiol
Chelator: DOTA
Share your feedback
Help us improve your experience